Lorlatinib in ROS1+ NSCLC With Brain Metastasis
NCT07083687
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer (NSCLC)
Interventions
DRUG:
Lorlatinib 100 mg
Sponsor
Hunan Cancer Hospital